AU2002346581A1 - Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment - Google Patents

Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment

Info

Publication number
AU2002346581A1
AU2002346581A1 AU2002346581A AU2002346581A AU2002346581A1 AU 2002346581 A1 AU2002346581 A1 AU 2002346581A1 AU 2002346581 A AU2002346581 A AU 2002346581A AU 2002346581 A AU2002346581 A AU 2002346581A AU 2002346581 A1 AU2002346581 A1 AU 2002346581A1
Authority
AU
Australia
Prior art keywords
monoclonal antibody
multiple sclerosis
antibody therapy
antagonist anti
sclerosis treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002346581A
Other versions
AU2002346581A8 (en
Inventor
Min F. Kwan
Lorianne K. Masuoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002346581A8 publication Critical patent/AU2002346581A8/en
Publication of AU2002346581A1 publication Critical patent/AU2002346581A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2002346581A 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment Abandoned AU2002346581A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33335501P 2001-11-26 2001-11-26
US60/333,355 2001-11-26
PCT/US2002/038164 WO2003045978A2 (en) 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment

Publications (2)

Publication Number Publication Date
AU2002346581A8 AU2002346581A8 (en) 2003-06-10
AU2002346581A1 true AU2002346581A1 (en) 2003-06-10

Family

ID=23302439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346581A Abandoned AU2002346581A1 (en) 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment

Country Status (5)

Country Link
EP (1) EP1455812A4 (en)
JP (1) JP2005510570A (en)
AU (1) AU2002346581A1 (en)
CA (1) CA2466931A1 (en)
WO (1) WO2003045978A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1682178T3 (en) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Methods for therapy of cancers expressing the CD-40 antigen
EP1945260B1 (en) 2005-11-01 2012-10-24 Novartis AG Uses of anti-cd40 antibodies
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
CN102585011A (en) * 2012-02-10 2012-07-18 中国农业大学 Preparation method for dog alpha interferon derivative and application
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2021169423A (en) * 2020-04-15 2021-10-28 洋悦 松川 Method for administering pharmaceutical preparation
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230157315A (en) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 Compositions and methods for treating cytokine release syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Also Published As

Publication number Publication date
AU2002346581A8 (en) 2003-06-10
WO2003045978A2 (en) 2003-06-05
JP2005510570A (en) 2005-04-21
EP1455812A2 (en) 2004-09-15
CA2466931A1 (en) 2003-06-05
EP1455812A4 (en) 2006-03-22
WO2003045978A3 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
EP1391464A4 (en) Anti-cd40 monoclonal antibody
IL158831A0 (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP1482972A4 (en) Treatment of immunological disorders using anti-cd30 antibodies
IL149701A0 (en) Use of anti-ctla-4 antibodies
IL166244A0 (en) Super humanized antibodies
IL200604A0 (en) Human monoclonal antibodies against cd30
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002346581A1 (en) Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AU2003277832A1 (en) Humanized tissue factor antibodies
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
AU2002326991A1 (en) Methods for treating multiple sclerosis
AU2002360696A1 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
EP1446416A4 (en) Tumor specific monoclonal antibodies
AU2002211364A1 (en) Human anti-cd40 antibodies
AU2002227175A1 (en) Anti-tenascin monoclonal antibody therapy for lymphoma
TW517526U (en) Structure of plate for trapping mouse
AUPR589001A0 (en) An antibody cancer therapeutic
AU2002250845A1 (en) Pharmaceutical composition for treating multiple sclerosis
AU2002304743A1 (en) Cancer treatment by using fap-alpha specific antibodies
GB0121727D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase